SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/11/23 YIELD10 Bioscience, Inc. 424B4 1:400K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 424B4 Prospectus - Info Previously Omitted & New Facts HTML 309K or Events
tm2322476-5_424b4 - none - 4.6875231s |
| | |
Per Share and
Accompanying Common Warrant |
| |
Total(1)
|
| ||||||
Public offering price
|
| | | $ | 0.6500 | | | | | $ | 3,737,500.00 | | |
Placement agent fees(1)
|
| | | $ | 0.0455 | | | | | $ | 226,817.50 | | |
Proceeds, before expenses, to us
|
| | | $ | 0.6045 | | | | | $ | 3,510,682.50 | | |
|
Maxim Group LLC
|
| |
Lake Street
|
|
| | | | | 1 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 22 | | | |
| | | | | 26 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | |
|
Platform
|
| |
Product
|
| |
Main Markets
|
| |
Revenue Potential
|
| |
Status
|
|
| Elite Camelina | | | Feedstock oil | | |
▪
Renewable diesel
▪
Aviation biofuel
$27 billion
|
| |
$180 million - $1 billion
|
| |
▪
Early Commercial
▪
Accelerating elite variety development
▪
Focus: US, Canada
▪
Biofuel partner outreach
|
|
| Elite PHA Camelina | | | PHA Bioplastics Feedstock oil | | |
▪
Single use plastic
$200 billion
|
| |
$3.6 billion
|
| |
▪
Trait optimization
▪
Pilot process development
▪
Partner outreach
|
|
| Elite Omega-3 Camelina | | | Omega-3 Oil (DHA+EPA) | | |
▪
Aquaculture feed
▪
Nutrition
$4-6 billion
|
| |
$0.5 billion
|
| |
▪
Pre-commercial development
▪
Partner outreach
|
|
| | |
Actual
|
| |
Pro Forma
|
| |
Pro Forma
As Adjusted |
| |||||||||
| | |
(in thousands)
|
| |||||||||||||||
Cash and cash equivalents
|
| | | $ | 1,809 | | | | | $ | 4,532 | | | | | $ | 7,676 | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | |
Common stock, $0.01 par value per share: 60,000,000 shares authorized as of March 31, 2023; 5,078,557 shares issued and outstanding as of March 31, 2023; 6,085,267 shares issued and outstanding pro forma 11,835,267 shares issued and outstanding pro forma as adjusted
|
| | | | 51 | | | | | | 61 | | | | | | 119 | | |
Additional paid-in capital
|
| | | | 404,803 | | | | | | 407,516 | | | | | | 410,602 | | |
Accumulated deficit
|
| | | | (403,479) | | | | | | (403,479) | | | | | | (403,479) | | |
Accumulated other comprehensive loss
|
| | | | (232) | | | | | | (232) | | | | | | (232) | | |
Total stockholders’ equity
|
| | | | 1,143 | | | | | | 3,866 | | | | | | 7,010 | | |
Total capitalization
|
| | | $ | 1,143 | | | | | $ | 3,866 | | | | | $ | 7,010 | | |
|
Public offering price per unit
|
| | | | | | | | | $ | 0.65 | | |
|
Historical net tangible book value per share
|
| | | $ | 0.23 | | | | | | | | |
|
Increase per share attributable to pro forma adjustments
|
| | | | 0.41 | | | | | | | | |
|
Pro forma net tangible book value per share at March 31, 2023
|
| | | $ | 0.64 | | | | | | | | |
|
Increase (decrease) in pro forma net tangible book value per share attributable
to new investors |
| | | | | | | | | | (0.05) | | |
|
Pro forma as adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | 0.59 | | |
|
Dilution per share to investors purchasing securities in this offering
|
| | | | | | | | | $ | 0.06 | | |
| | |
Per Unit
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | 0.6500 | | | | | $ | 3,737,500.00 | | |
Placement agent fees
|
| | | $ | 0.0455 | | | | | $ | 226,817.50 | | |
Proceeds, before expenses, to us
|
| | | $ | 0.6045 | | | | | $ | 3,510,682.50 | | |
This ‘424B4’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/31/23 | ||||
9/30/23 | ||||
8/15/23 | ||||
8/14/23 | ||||
Filed on: | 8/11/23 | EFFECT | ||
8/10/23 | EFFECT | |||
7/18/23 | 424B3 | |||
7/13/23 | S-1 | |||
7/12/23 | S-1/A | |||
6/30/23 | 4, S-1 | |||
5/18/23 | 8-K | |||
5/12/23 | 10-Q | |||
5/3/23 | 8-K | |||
4/27/23 | 8-K | |||
3/31/23 | 10-Q, 4 | |||
12/31/22 | 10-K, 4 | |||
12/31/21 | 10-K, 4 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/02/23 YIELD10 Bioscience, Inc. 8-K:8,9 8/02/23 11:5.7M Toppan Merrill/FA 5/30/23 YIELD10 Bioscience, Inc. 8-K©:5,9 5/25/23 11:326K 5/19/23 YIELD10 Bioscience, Inc. 8-K:3 5/18/23 10:159K 5/12/23 YIELD10 Bioscience, Inc. 10-Q 3/31/23 64:4.6M 5/04/23 YIELD10 Bioscience, Inc. 8-K:1,3,8,9 5/03/23 15:921K Toppan Merrill/FA 5/03/23 YIELD10 Bioscience, Inc. 8-K:1 5/03/23 10:182K Toppan Merrill/FA 5/01/23 YIELD10 Bioscience, Inc. 8-K:1,2,9 4/27/23 12:466K 4/06/23 YIELD10 Bioscience, Inc. DEF 14A 4/05/23 1:832K 3/14/23 YIELD10 Bioscience, Inc. 10-K 12/31/22 82:8.3M 1/24/23 YIELD10 Bioscience, Inc. 8-K:1,9 1/23/23 12:491K Toppan Merrill/FA 11/06/06 YIELD10 Bioscience, Inc. 8-A12B 11/03/06 1:22K Toppan Merrill/FA |